Biopharma Companies Gain Faster Intelligence Through Direct Access to Raw Data, Bypassing Traditional Analysts.

Biopharma companies are increasingly utilizing direct raw data platforms to access and analyze intelligence, a shift away from relying on traditional analysts and their methodologies. This trend allows for potentially faster and more accurate data-driven decision-making within the industry. DrugPatentWatch reports that biopharma companies are now able to bypass intermediaries and gain direct access to raw data. Previously, these companies relied on analysts who utilized what the company describes as “outdated data.” The use of direct raw data platforms intends to allow companies to obtain biopharma intelligence with greater speed. Additional information on this shift is available on the DrugPatentWatch website.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Biosimilar Supply Chains Face Hurdles: Contract Manufacturing Partnerships Rise Amidst FDA’s Strict Guidelines Pharmacovigilance Gaining Importance in Generic Drug Development for Early Detection of Safety Issues Icotrokinra Trials Show Statistically Significant Improvement in Scalp and Genital Psoriasis UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates

Author

Mark Chiang